Supplementary Figure S1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Helen Clark(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Oladapo Yeku(Harvard University), Amy Bregar, Amanda Nash(Rice University), Oleg A. Igoshin(Rice University), Juan C. Amador-Molina, Samira Aghlara-Fotovat(Integrated BioTherapeutics (United States)), Claudio Dansky Ullmann(Multimeric Biotherapeutics (United States)), Omid Veiseh(Rice University), José Oberholzer(University Hospital of Zurich), Jonathon DeBonis(Rice University), Travis T. Sims(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Ira Joshi(TransUnion (United States)), Rima Chakrabarti, Peter Rios(TransUnion (United States)), Lauren Jansen, Andrew M. Blakely(National Institutes of Health), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Daisy Lopez, Jake Schladenhauffen, Hafsa Nasir, Karen Andreas, Manish Jain, Ryan Newman, Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Kelly Rangel, Cara Mathews(Brown University)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
|Advanced Drug Delivery Reviews|2009|1.8k
Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates
|Nature Materials|2015|895
Electrospun chitosan-based nanofibers and their cellular compatibility
|Biomaterials|2005|888